Dr Reddy's Laboratories Operating Income 2012-2026 | RDY
Dr Reddy's Laboratories annual/quarterly operating income history and growth rate from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Dr Reddy's Laboratories operating income for the quarter ending March 31, 2026 was $-0.027B, a 113.62% decline year-over-year.
- Dr Reddy's Laboratories operating income for the twelve months ending March 31, 2026 was $0.539B, a 35.99% decline year-over-year.
- Dr Reddy's Laboratories annual operating income for 2026 was $0.571B, a 32.16% decline from 2025.
- Dr Reddy's Laboratories annual operating income for 2025 was $0.842B, a 3.69% increase from 2024.
- Dr Reddy's Laboratories annual operating income for 2024 was $0.812B, a 16.83% increase from 2023.
|
Dr Reddy's Laboratories Annual Operating Income (Millions of US $) |
|
|---|---|
| 2026 | $571 |
| 2025 | $842 |
| 2024 | $812 |
| 2023 | $695 |
| 2022 | $389 |
| 2021 | $449 |
| 2020 | $435 |
| 2019 | $302 |
| 2018 | $183 |
| 2017 | $208 |
| 2016 | $447 |
| 2015 | $422 |
| 2014 | $435 |
| 2013 | $355 |
| 2012 | $365 |
|
Dr Reddy's Laboratories Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-27 |
| 2025-12-31 | $159 |
| 2025-09-30 | $201 |
| 2025-06-30 | $205 |
| 2025-03-31 | $197 |
| 2024-12-31 | $221 |
| 2024-09-30 | $209 |
| 2024-06-30 | $215 |
| 2024-03-31 | $175 |
| 2023-12-31 | $207 |
| 2023-09-30 | $215 |
| 2023-06-30 | $215 |
| 2023-03-31 | $139 |
| 2022-12-31 | $200 |
| 2022-09-30 | $202 |
| 2022-06-30 | $154 |
| 2022-03-31 | $11 |
| 2021-12-31 | $125 |
| 2021-09-30 | $164 |
| 2021-06-30 | $90 |
| 2021-03-31 | $106 |
| 2020-12-31 | $112 |
| 2020-09-30 | $123 |
| 2020-06-30 | $108 |
| 2020-03-31 | $112 |
| 2019-12-31 | $103 |
| 2019-09-30 | $104 |
| 2019-06-30 | $116 |
| 2019-03-31 | $82 |
| 2018-12-31 | $80 |
| 2018-09-30 | $72 |
| 2018-06-30 | $68 |
| 2018-03-31 | $40 |
| 2017-12-31 | $78 |
| 2017-09-30 | $59 |
| 2017-06-30 | $6 |
| 2017-03-31 | $55 |
| 2016-12-31 | $85 |
| 2016-09-30 | $51 |
| 2016-06-30 | $17 |
| 2016-03-31 | $68 |
| 2015-12-31 | $115 |
| 2015-09-30 | $143 |
| 2015-06-30 | $121 |
| 2015-03-31 | $132 |
| 2014-12-31 | $115 |
| 2014-09-30 | $89 |
| 2014-06-30 | $104 |
| 2014-03-31 | $88 |
| 2013-12-31 | $129 |
| 2013-09-30 | $118 |
| 2013-06-30 | $63 |
| 2013-03-31 | $100 |
| 2012-12-31 | $75 |
| 2012-09-30 | $113 |
| 2012-06-30 | $70 |
| 2012-03-31 | $163 |
| 2011-12-31 | $142 |
| 2011-09-30 | $43 |
| 2011-06-30 | $66 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |